Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro

Journal of Pharmacology and Experimental Therapeutics

Volumn 339, Issue 2, 2011, Pages 589-596

  Abell, Lynn M ^a   Liu, Eddie C K ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLOROPHENYL) 2 (4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDIN 5 YL)ACETIC ACID; 2 OXO CLOPIDOGREL; CLOPIDOGREL; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; KETOCONAZOLE; PRASUGREL; UNCLASSIFIED DRUG;

ARTICLE; BIOSENSOR; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION;

ARYL HYDROCARBON HYDROXYLASES; BACULOVIRIDAE; BIOSENSING TECHNIQUES; BIOTRANSFORMATION; BLOOD PLATELETS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ASSAYS; HUMANS; MICROSOMES; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET-RICH PLASMA; THIENOPYRIDINES; THIOPHENES; TICLOPIDINE;

EID: 80054785029     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.184895     Document Type: Article

References (26)

1. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, and Winters KJ (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429-2436. (Pubitemid 350154353)
2. Caplain H, Donat F, Gaud C, and Necciari J (1999) Pharmacokinetics of clopidogrel. Semin Thromb Hemost 25:25-28. (Pubitemid 29350288)
3. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339.
4. Clarke TA and Waskell LA (2003) The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 31:53-59. (Pubitemid 36735258)
5. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, et al. (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309-317.
6. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, and Salazar DE (2007) Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 81:735-741. (Pubitemid 46625113)
7. Hasegawa M, Sugidachi A, Ogawa T, Isobe T, Jakubowski JA, and Asai F (2005) Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (Prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost 94:593-598. (Pubitemid 41300857)
8. Herbert JM, Frehel D, Vallee E, Kieffer G, Gouy D, Berger Y, Necciari J, Defreyn G, and Maffrand JP (1993) Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 11:180-198. (Pubitemid 23338380)
9. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, and Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247. (Pubitemid 44497506)
10. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, and Kurihara A (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92-99.
11. Kim KA, Park PW, Hong SJ, and Park JY (2008a) The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 84:236-242.
12. Kim KA, Park PW, and Park JY (2008b) Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol 64:589-597.
13. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, et al. (2009) Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-362.
14. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP, and Picard C (2002) Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30:1288-1295. (Pubitemid 35265838)
15. Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, and Ring BJ (2006) Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 34:600-607.
16. Richter T, Mü rdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, and Zanger UM (2004) Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 308:189-197.
17. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, and Herbert JM (1994) The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 72:313-317. (Pubitemid 24251300)
18. Savi P, Labouret C, Delesque N, Guette F, Lupker J, and Herbert JM (2001) P2Y12, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 283:379-383. (Pubitemid 32924702)
19. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, Pascal M, and Herbert JM (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891-896.
20. Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Hervé C, Uzabiaga MF, Pereillo JM, Culouscou JM, Bono F, Ferrara P, et al. (2006) The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci USA 103:11069-11074. (Pubitemid 44148419)
21. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L, et al. (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363-375.
22. Sugidachi A, Asai F, Yoneda K, Iwamura R, Ogawa T, Otsuguro K, and Koike H (2001) Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine- type Gi-linked P2T antagonist, CS-747. Br J Pharmacol 132:47-54. (Pubitemid 32128433)
23. Tuffal G, Roy S, Lavisse M, Brasseur D, Schofield J, Delesque Touchard N, Savi P, Bremond N, Rouchon MC, Hurbin F, et al. (2011) An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb Haemost 105:696-705.
24. Turpeinen M, Tolonen A, Uusitalo J, Jalonen J, Pelkonen O, and Laine K (2005) Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 77:553-559. (Pubitemid 40824968)
25. Williams ET, Jones KO, Ponsler GD, Lowery SM, Perkins EJ, Wrighton SA, Ruterbories KJ, Kazui M, and Farid NA (2008) The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos 36:1227-1232. (Pubitemid 351929304)
26. Zahno A, Brecht K, Bodmer M, Bur D, Tsakiris DA, and Krähenbühl S (2010) Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. Br J Pharmacol 161:393-404.